New drug cuts relapse risk for patients with rare immune disorder, study shows
June 04, 2026
June 04, 2026
STANFORD, California, June 4 -- Stanford University School of Medicine posted the following news:
* * *
New drug cuts relapse risk for patients with rare immune disorder, study shows
*
Stanford Medicine researchers and their colleagues found that a new drug, obexelimab, significantly reduces the risk of relapse in patients with IgG4-related disease, a rare chronic immune condition often misdiagnosed as cancer.
People with IgG4-rel . . .
* * *
New drug cuts relapse risk for patients with rare immune disorder, study shows
*
Stanford Medicine researchers and their colleagues found that a new drug, obexelimab, significantly reduces the risk of relapse in patients with IgG4-related disease, a rare chronic immune condition often misdiagnosed as cancer.
People with IgG4-rel . . .